Featured Research

from universities, journals, and other organizations

New research model to aid search for degenerative disease cures

Date:
October 2, 2012
Source:
University of California - Irvine
Summary:
Efforts to treat disorders like Lou Gehrig's disease, Paget's disease, inclusion body myopathy and dementia will receive a considerable boost from a new research model.

Efforts to treat disorders like Lou Gehrig's disease, Paget's disease, inclusion body myopathy and dementiawill receive a considerable boost from a new research model created by UC Irvine scientists.

The team, led by pediatrician Dr. Virginia Kimonis, has developed a genetically modified mouse that exhibits many of the clinical features of human diseases largely triggered by mutations in the valosin-containing protein.

The mouse model will let researchers study how these now-incurable, degenerative disorders progress in vivo and will provide a platform for translational studies that could lead to lifesaving treatments.

"Currently, there are no effective therapies for VCP-associated diseases and related neurodegenerative disorders," said Kimonis, a professor of pediatrics who specializes in genetics and metabolism. "This model will significantly spark new approaches to research directed toward the creation of novel treatment strategies."

She and her team reported their discovery Sept. 28 online in PLOS ONE, a peer-reviewed, open-access journal.

The UCI researchers -- from pediatrics, neurology, pathology and radiological sciences -- specifically bred the first-ever "knock-in" mouse in which the normal VCP gene was substituted with one containing the common R155H mutation seen in humans with VCP-linked diseases. Subsequently, these mice exhibited the same muscle, brain and spinal cord pathology and bone abnormalities as these patients.

VCP is part of a system that maintains cell health by breaking down and clearing away old and damaged proteins that are no longer necessary. Mutations in the VCP gene disrupt the demolition process, and, as a result, excess and abnormal proteins may build up in muscle, bone and brain cells. These proteins form clumps that interfere with the cells' normal functions and can lead to a range of disorders.

Another study carried out by members of this group -- and published in August in the journal Cell Death & Disease -- made use of these genetically altered mice to examine the development of Lou Gehrig's disease, or ALS. The researchers, led by Dr. Hong Yin and Dr. John Weiss in UCI's Department of Neurology, documented slow, extensive pathological changes in the spinal cord remarkably similar to changes observed in other animal models of ALS as well as in human patients. ALS research is currently limited by a paucity of animal models in which disease processes can be studied.

Genetically modified mice have become important research models in the effort to cure human ailments. Mice bred to exhibit the brain pathology of Alzheimer's disease, for example, have dramatically sped up the race to advance new treatments -- one such model was developed at UCI. And many cancer therapies were created and tested using genetically altered mice.

Angele Nalbandian, Katrina Llewellyn, Mallikarjun Badadani, Robert Edwards, Christopher Nguyen, Jogeshwar Mukherjee and Dr. Tahseen Mozaffar of UCI, along with Masashi Kitazawa of UC Merced, Negar Khanlou of UCLA and Giles Watts of the U.K.'s University of East Anglia, also contributed to the PLOS ONE study, which received support from the National Institutes of Health via grant AR 050236, the Muscular Dystrophy Association and the Paget Foundation.


Story Source:

The above story is based on materials provided by University of California - Irvine. Note: Materials may be edited for content and length.


Journal Reference:

  1. Angθle Nalbandian, Katrina J. Llewellyn, Masashi Kitazawa, Hong Z. Yin, Mallikarjun Badadani, Negar Khanlou, Robert Edwards, Christopher Nguyen, Jogeshwar Mukherjee, Tahseen Mozaffar, Giles Watts, John Weiss, Virginia E. Kimonis. The Homozygote VCPR155H/R155H Mouse Model Exhibits Accelerated Human VCP-Associated Disease Pathology. PLoS ONE, 2012; 7 (9): e46308 DOI: 10.1371/journal.pone.0046308

Cite This Page:

University of California - Irvine. "New research model to aid search for degenerative disease cures." ScienceDaily. ScienceDaily, 2 October 2012. <www.sciencedaily.com/releases/2012/10/121002145748.htm>.
University of California - Irvine. (2012, October 2). New research model to aid search for degenerative disease cures. ScienceDaily. Retrieved July 30, 2014 from www.sciencedaily.com/releases/2012/10/121002145748.htm
University of California - Irvine. "New research model to aid search for degenerative disease cures." ScienceDaily. www.sciencedaily.com/releases/2012/10/121002145748.htm (accessed July 30, 2014).

Share This




More Health & Medicine News

Wednesday, July 30, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Health Insurers' Profits Slide

Health Insurers' Profits Slide

Reuters - Business Video Online (July 30, 2014) — Obamacare-related costs were said to be behind the profit plunge at Wellpoint and Humana, but Wellpoint sees the new exchanges boosting its earnings for the full year. Fred Katayama reports. Video provided by Reuters
Powered by NewsLook.com
Concern Grows Over Worsening Ebola Crisis

Concern Grows Over Worsening Ebola Crisis

AFP (July 30, 2014) — Pan-African airline ASKY has suspended all flights to and from the capitals of Liberia and Sierra Leone amid the worsening Ebola health crisis, which has so far caused 672 deaths in Guinea, Liberia and Sierra Leone. Duration: 00:43 Video provided by AFP
Powered by NewsLook.com
At Least 20 Chikungunya Cases in New Jersey

At Least 20 Chikungunya Cases in New Jersey

AP (July 30, 2014) — At least 20 New Jersey residents have tested positive for chikungunya, a mosquito-borne virus that has spread through the Caribbean. (July 30) Video provided by AP
Powered by NewsLook.com
Generics Eat Into Pfizer's Sales

Generics Eat Into Pfizer's Sales

Reuters - Business Video Online (July 29, 2014) — Pfizer, the world's largest drug maker, cut full-year revenue forecasts because generics could cut into sales of its anti-arthritis drug, Celebrex. Fred Katayama reports. Video provided by Reuters
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

    Environment News

    Technology News



      Save/Print:
      Share:  

      Free Subscriptions


      Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

      Get Social & Mobile


      Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

      Have Feedback?


      Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
      Mobile iPhone Android Web
      Follow Facebook Twitter Google+
      Subscribe RSS Feeds Email Newsletters
      Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins